07 October 2021

License agreement secured in Republic of Korea for Accrufer®

Shield Therapeutics plc, announces that it has entered into an exclusive license agreement for Accrufer® with KOREA PHARMA CO.,LTD (“Korea Pharma”) in the Republic of Korea (“South Korea” or “Korea”).  Alongside the financial terms of the license, Korea Pharma will undertake and pay for all activities to achieve marketing authorisation and then commercialise Accrufer® in Korea. For further details click here.

Back to News